Andreas Kronbichler
1*1 Medical University Innsbruck, Department of Internal Medicine IV, Nephrology and Hypertension, Innsbruck, Au
*Corresponding Author: *Corresponding author: Dr. Andreas Kronbichler, Medical University Innsbruck, Department of Internal Medicine IV, Nephrology and Hypertension, Anichstraße 35, 6020 Innsbruck, Austria., Email:
andreas.kronbichler@i-med.ac.at
Abstract
Implication for health policy/practice/research/medical educationRituximab has emerged as an alternative in the induction of remission in ANCA-associated vasculitis. Recent studies revealed a non-inferiority of a single dose rituximab in addition to a six month course of steroids compared to standard therapy after a follow-up period of 18 months. The results of the RAVE-ITN trial are encouraging and a special cohort of patients might benefit from this protocol.